Experience of use of 2-ethyl-6-methyl-3-hydroxypyridine succinate in complex therapy of stable angina

Abstract

The aim — to evaluate the efficacy and tolerability of the use of different doses (200 and 500 mg/day) of 2‑ethyl‑6‑methyl‑3‑hydroxypyridine succinate (Venokor, Lekhim, Ukraine) in the complex therapy of patients with coronary heart disease and stable angina pectoris of II — III functional class.Materials and methods. The study involved 60 patients with ischemic heart disease and stable angina pectoris of II — III functional class aged 48 to 76 years. The patients were divided into three groups. Patients of the 1st (n = 20) and 2nd (n = 20) groups, in addition to the medical treatment of ischemic heart disease according to the recommendations, were prescribed 2‑ethyl‑6‑methyl‑3‑hydroxypyridine succinate parenterally at a dose of 200 and 500 mg/day, respectively. Patients of the control group received only standard treatment (b‑blockers, calcium antagonists, acetylsalicylic acid, statins). The effect of treatment was evaluated on the 14th day from the beginning of therapy.Results and discussion. The number of angina attacks per week decreased with the use of 2‑ethyl‑6‑methyl‑3‑hydroxypyridine succinate at a dose of 200 and 500 mg/day compared to patients who were prescribed standard angina therapy (p < 0.05 and p < 0.01, respectively). The need for nitroglycerin tablets decreased statistically significantly in the two main groups compared to the control group (p < 0.01 and p < 0.001, respectively). This decrease was statistically significantly (p < 0.001) greater in patients of the 2nd group compared to the patients of the 1st group. Patients of the two main groups improved their quality of life scores on the scales of pain intensity (p < 0.01), physical functioning, overall mental health (p < 0.01), total physical health score of the SF‑36 questionnaire (p = 0.005).Conclusions. Addition of 2‑ethyl‑6‑methyl‑3‑hydroxypyridine succinate to a standard treatment regimen for patients with coronary heart disease and stable angina pectoris of II — III functional class helps to reduce the need for nitroglycerin and improves patients’ quality of life.